Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder

NCT04466345 · Completed

Last updated 2026-05-28

This clinical trial is testing whether the medication semaglutide can help improve thinking and memory problems in adults with major depressive disorder.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 72 people

Who can join Ages 18–60 · all sexes

Timeline Started 2021-10 · est. completion 2024-12

Where 1 site · Canada

What this study is testing ClinicalTrials.gov NCT04466345 ↗

Description as written by the study sponsor.

This study will examine whether semaglutide may improve cognitive function in individuals with major depressive disorder (MDD).

Treatments tested

Semaglutide Biologic

3 mg/day for 4 weeks, increased to 7 mg/day for 4 more weeks and titrated to 14 mg/day for the subsequent 8 weeks
Placebo Biologic

Semaglutide placebo capsules

Main thing measured	Executive Function Composite Score
Sponsor	University Health Network, Toronto
Conditions studied	Major Depressive Disorder
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04466345 ↗